tirzepatide on shortage list Lilly's weight-loss drug removed from FDA's END OF TIRZEPATIDE COMPOUNDING? FDA

(en) Chen, Elaine, Eli Lilly's obesity drug Zepbound shows benefits in heart failure patients

This can leave patients worse off with less lean mass, a lower basal metabolic rate, and greater difficulty achieving future weight loss

Do not stop taking Mounjaro without medical advice , as this may lead to worsening glycaemic control or weight regain

Originally developed by Eli Lilly, it is FDA-approved as Mounjaro (for diabetes) and Zepbound (for weight management)

Both Qsymia and GLP-1 receptor agonists like semaglutide and tirzepatide are FDA-approved for chronic weight management

Rashes: Small bumps, blisters, or patches of irritated skin can appear